- This event has passed.
Winners of BIRD Funding
May 17, 2018, 2019 | 6:00 pm - 8:00 pm
The NEIBC community is cordially invited to meet and listen to three amazing stories by
The Winners of BIRD Funding:
- Jonathan (Yoni) Aharon, CFO, Formlabs Inc.
- Dr. Rachel Legmann, Senior Manager, Cell Culture SUT-Process Development lab, Pall Life Sciences Inc.
- Dr. Udi Meirav, Co-Founder & CEO, enVerid System Inc.
This event is free and open to the public
Location: ZAG-S&W, 1 Post Office Square, Boston | Time: 6:00pm – 8:00pm | Date: Thursday, May 17, 2018
Jonathan (Yoni) Aharon, CFO
Yoni as the CFO at Formlabs, the leading professional 3D printer manufacturer, is responsible for overall financial strategy and operations. Over his 4yrs tenure at Formlabs, he has scaled Formlabs 10X as a member of the senior leadership team, and has executed over $70M in equity & debt financing and two (2) acquisitions.
Prior to Formlabs, he spent several years in Finance, Operations, and Sales leadership roles in both venture backed start-ups and mid-market corporate America. In pre-historic times, Yoni founded and led a concert and record production business in Israel, where he first got hooked on building businesses. Yoni holds an MBA with distinction from Columbia Business School, and a B.A. in Computer Science from IDC Herzliya, Israel, where he graduated from the Sam Zell Entrepreneurship Program, and received the Efi Arazi Entrepreneurial fellowship.
Rachel Legmann PhD, Senior Manager, Cell Culture SUT-Process Development lab
Dr. Rachel Legmann, completed her Ph.D. in Food Engineering and Biotechnology at the Technicon-Israel Institute of Technology, Israel. In 1996 she joined the Microbiology & Molecular Genetics department at Harvard Medical School and was part of the development team for large scale manufacturing processes for new recombinant protein vaccines. In 2002 Rachel joined the pre-clinical contract research organization, SBH Sciences as Principal scientist. Her contributions included optimizing existing cell culture processes for better product yield and quality as well as expanded new products line and services. Rachel joined Seahorse Biosciences in 2007 as an associate director. As a member of the management team her responsibilities included designing and optimizing upstream and downstream processes for a new high throughput cell culture automated micro-bioreactor automated platform, and developing multiple cell based metabolic assays and kits for the Extracellular-Flux cell metabolism analyzer. In 2013 she joined Goodwin Biotechnology, a Contract Manufacturing Organization (CMO), as an upstream process development manager. Rachel joined Pall in 2014 and currently serves as a process development services senior lab manager in charge of upstream and downstream process development, scale-up, continuous bioprocessing and manufacturing support activities for gene therapy and biologic market. Rachel is focused on combining biological and engineering aspects for maximizing process efficiencies and product quality.
Udi Meirav PhD, Co-Founder & CEO
enVerid Systems Inc.
Dr. Udi Meirav is co-founder and Chief Executive Officer of Boston-based enVerid Systems, a technology leader in Air Care, which has developed and commercialized groundbreaking HVAC Load Reduction (HLR®) technology – modular, intelligent scrubbers for indoor air that enable dramatic reduction in HVAC energy consumption and improved indoor air quality in commercial buildings. Dr. Meirav has a multidisciplinary background with executive experience in technology and finance. Before enVerid, he served as CEO of Boston based Luminus Devices, an independent developer and manufacturer of high performance LEDs for solid state lighting applications, a company he had led from its inception into a globally recognized technology leader and manufacturer. He has also worked as an investor at Stata Venture Partners, an early stage venture capital fund, and Strategic Decision Group, a premier global strategy consulting firm. Dr. Meirav has served on numerous boards of directors of other startup companies ranging from semiconductors and cybersecurity to oncology and healthcare IT. Earlier in life he served 4 years in IDF’s Unit 8200. He has a PhD in Physics from MIT and began his career as a nanotechnology research physicist.
BIRD is an acronym for Israel-U.S. Binational Industrial Research and Development. The BIRD Foundation’s mission is to stimulate, promote and support industrial R&D of mutual benefit to the U.S. and Israel.
The BIRD Foundation was established by the U.S. and Israeli governments in 1977 to generate mutually beneficial cooperation between U.S. and Israeli companies, including start-ups and established organizations. BIRD provides both matchmaking support between U.S. and Israeli companies, as well as funding covering up to 50 percent of project development costs, up to $1M per project. BIRD takes no equity in the companies.
BIRD’s scope extends to Agriculture, Communications, Construction Technologies, Electronics, Electro-optics, Life Sciences, Software, Homeland Security, Renewable and Alternative Energy and other technology sectors.
BIRD supports approximately 20 projects annually. The cumulative sales of products developed through BIRD projects have exceeded $10 billion.
Since its inception in 1977, BIRD has approved over 950 projects with leading companies in the U.S., for example: ADM, American Red Cross, Applied Materials, Avaya, Bayer Pharmaceutical, Becton Dickinson, Bio-Rad Laboratories, Eastman Kodak, General Dynamics, General Electric, Guidant, IBM, J&J, KLA- Tencor, Molex, Motorola, Procter & Gamble, SanDisk, Spansion, Telcordia, Texas Instruments, Tyco and many others.
To Register Click HERE